Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, which in turn modulates potassium channel activity and induces TXNIP-dependent potassium deficiency. Additionally, HL23 impedes the advancement and spread of HCC and demonstrates a synergistic effect when combined with Sorafenib, exhibiting greater potency than the duo of Sorafenib and Vorinostat [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
5 mg | お問い合わせ | ¥ 314,500 |
50 mg | お問い合わせ | ¥ 638,000 |
100 mg | お問い合わせ | ¥ 849,500 |
説明 | HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, which in turn modulates potassium channel activity and induces TXNIP-dependent potassium deficiency. Additionally, HL23 impedes the advancement and spread of HCC and demonstrates a synergistic effect when combined with Sorafenib, exhibiting greater potency than the duo of Sorafenib and Vorinostat [1]. |
分子量 | 712.83 |
分子式 | C44H44N2O7 |
CAS No. | 1448355-15-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HL23 1448355-15-4 Others Inhibitor inhibitor inhibit